Evidence map›Paper›PMID 40033345›Full record

ArticleInfectious diseases of poverty2025

Best practices for engaging with affected communities: chronic hepatitis B as a case study.

Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah and 11 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Time for a globally unified chronic HBV terminology?JHEP reports : innovation in hepatology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Thomas TuStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney at Westmead Hospital, Westmead, NSW, Australia. t.tu@sydney.edu.au.ORCID http://orcid.org/0000-0002-0482-4387
Nafisa YussfHepatitis B Voices Australia, Melbourne, VIC, Australia.
Lien TranHepatitis B Voices Australia, Melbourne, VIC, Australia.
Kim NgoHepatitis B Voices Australia, Melbourne, VIC, Australia.
Su WangHepatitis B Foundation, Doylestown, PA, USA.
Adi MondelASHM Health, Sydney, Australia.
Isabelle PurcellASHM Health, Sydney, Australia.
Jacki ChenHepatitis B Foundation, Doylestown, PA, USA.
Wendy LoHepatitis B Foundation, Doylestown, PA, USA.
Bright AnsahHepatitis B Foundation, Doylestown, PA, USA.
Kenneth KabagambeHepatitis B Foundation, Doylestown, PA, USA.
Soumen BasuHepatitis B Foundation, Doylestown, PA, USA.
Dee LeeWorld Hepatitis Alliance, London, UK.
Supa ChantschoolHep B Companion, London, UK.
Chris MunozHepatitis B Foundation, Doylestown, PA, USA.
Ivana DragojevicEuropean Liver Patients' Association, Brussels, Belgium.
Marko KorenjakEuropean Liver Patients' Association, Brussels, Belgium.
Fiona Borondy-JenkinsHepatitis B Foundation, Doylestown, PA, USA.
Yasmin IbrahimHepatitis B Foundation, Doylestown, PA, USA.
Beatrice ZovichHepatitis B Foundation, Doylestown, PA, USA.
Chari CohenHepatitis B Foundation, Doylestown, PA, USA.

Funding

Paul and Valeria Ainsworth Precision Medicine Fellowship
6 · The paper itself

Abstract

Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment (8% of eligible individuals). As with many health conditions, engagement with the affected community is crucial for designing, promoting, and advocating for effective solutions in the health system. However, engagement with the affected community remains difficult in many instances due to variable understanding of the roles, capacities, and expertise of people with lived experience. Through community-led consensus, we provide here several practical approaches for how public health, clinical, scientific, industrial, and policy-making bodies should engage with the hepatitis B affected community. These expert consensus practices have been developed by people living with hepatitis B and/or advocating for them. We suggest that these practices should be incorporated into any engagements with communities affected by hepatitis B and can be generalisable to other health conditions.

Indexed as

Community ParticipationHepatitis B, ChronicHumansPublic HealthCollaborative partnershipCommunity researchConsumer engagementExpert consensusHepatitis BLived experiencePatient advocacyPatient representationPolicy development

Identifiers

PMID40033345
PMCPMC11877849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.